MarketInOut Stock Screener Log In | Sign Up
 

AnaptysBio Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/25/2026
AnaptysBio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,495.81 mln
Float27.90 mln
Earnings Date11/10/2026

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-2.72
Likely reliable

1-Year Forecast

88.50
Transformational upside

Relative Strength

20 / 100
Significantly lagging

Debt / Equity

1.07
Elevated leverage

Pre-Tax Margin

-11%
Loss-making

Business Description

AnaptysBio Inc. is a San Diego-based biotechnology company working to develop treatments for autoimmune and inflammatory conditions. Its pipeline includes several promising drug candidates at various stages of clinical testing, targeting diseases such as rheumatoid arthritis, psoriasis, celiac disease, and certain cancers. The company works alongside partners GSK and Vanda to advance its research programs from early discovery through clinical development.

Key Fundamentals

EPS-1.02
ROE-1,363
RPS3.66
ROIC82.57
ROA-7.42
Interest Cover0.49
EBITDA, mln145
EV / EBITDA8.70
EV / EBIT8.83
Revenue, mln238
EV / Revenue5.32

Quote Details

Last 51.00
Change -0.7 (-1.35%)
Open 52.38
Volume 437,400
Turnover 22,307,400
Average Volume 531,618

Financial Ratios

Pre-Tax Profit Margin-11
Leverage Ratio29.95
Current Ratio7.58
Price / Book118
Price / Tangible Book118
Price / Cash Flow80.97
Price / Free Cash Flow184
Debt / Equity1.07
Price / Sales6.44

Financial Strength

Altman Z-Score1.78
Piotroski F-Score 5 / 9
Beneish M-Score-2.72
1-Year Target Price88.50
Short Ratio14.67
Short % of Float40.68

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -7.61% 10 / 100   
1 Month -12.07% 18 / 100   
2 Months -11.32% 26 / 100   
6 Months 17.7% 74 / 100   
1 Year 246% 99 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us